Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Final DREAMM-3 Phase 3 Findings: Belantamab Mafodotin Compared With Pomalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

  • By

  • Meletios Athanasios Dimopoulos

  • Vania Hungria

  • Haitao Meng

  • Atanas Radinoff

  • Jian Li

  • Sosana Delimpasi

  • Ting Niu

  • Gabor Mikala

  • Tamas Masszi

  • Marcelo Capra

  • Michael Low

  • Angelo Maiolino

  • Yan Xu

  • Xavier Leleu

  • Vasiliki Pappa

  • Dominik Chraniuk

  • Tatiana Konstantinova

  • Iurii Osipov

  • Shawn Hakim

  • Chris Brawley

  • Gabriela Tubel

  • Astrid McKeown

  • Julia Boyle

  • Sumita Roy-Ghanta

  • Katja Weisel

  • October 17, 2026

Share

  • 1

    DREAMM-3 randomized 325 patients with relapsed or refractory multiple myeloma to belantamab mafodotin monotherapy or pomalidomide-dexamethasone.

  • 2

    At a median follow-up of approximately 22 months, median progression-free survival was 11.2 months with belantamab mafodotin and 7.0 months with pomalidomide-dexamethasone (HR, 0.87; 95% CI, 0.64-1.18

  • 3

    Median overall survival was 24.0 months with belantamab mafodotin and 22.9 months with pomalidomide-dexamethasone (HR, 0.98; 95% CI, 0.73-1.30).

  • 4

    Median duration of response was 25.3 months with belantamab mafodotin and 9.9 months with pomalidomide-dexamethasone.

  • 5

    Grade 3 to 4 adverse events occurred in 71% of patients receiving belantamab mafodotin and 66% receiving pomalidomide-dexamethasone; blurred vision occurred in 48% and 7%, respectively.

Original Source(s)

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

  • by Meletios Athanasios Dimopoulos, Vania Hungria, Haitao Meng, Atanas Radinoff, Jian Li, Sosana Delimpasi, Ting Niu, Gabor Mikala, Tamas Masszi, Marcelo Capra, Michael Low, Angelo Maiolino, Yan Xu, Xavier Leleu, Vasiliki Pappa, Dominik Chraniuk, Tatiana Konstantinova, Iurii Osipov, Shawn Hakim, Chris Brawley, Gabriela Tubel, Astrid McKeown, Julia Boyle, Sumita Roy-Ghanta, Katja Weisel

  • October 17, 2026

Related Content

Breast Cancer De-Escalation: Defining When Less Treatment Is Enough

The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.

  • by

  • October 13, 2026

  • 9 min
Bayesian network meta-analysis comparing efficacy of surgical gastrojejunostomy, endoscopic stenting, and EUS-guided gastroenterostomy for malignant gastric outlet obstruction

Weekly hippocampal diffusion changes during partial-brain radiation therapy for high-grade glioma: associations with dose and early memory change